Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer

Tobias Grob, Uwe Heilenkötter, Stefan Geist, +8

Breast Cancer Research and Treatment

Breast OncologyOncologyEngineeringTumor HeterogeneityMedicine +9

High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer

Patrick Lebok, MELIKE ÖZTÜRK, Uwe Heilenkötter, +12

Oncology Letters

Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer

Patrick Lebok, Aurelia von Hassel, Jan Meiners, +26

Aging

Breast OncologyPathologyCancer BiologyTumor BiologyStrong Lpcat1 Positivity +14

Partial PTEN deletion is linked to poor prognosis in breast cancer

Patrick Lebok, Valerie Kopperschmidt, Martina Kluth, +21

BMC Cancer

High homogeneity of MMR deficiency in ovarian cancer

Christoph Fraune, Janina Rosebrock, Ronald Simon, +18

Gynecologic Oncology

MedicineGynecologyOncologyTumor BiologyEndocrine-related Cancer +2

Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome

Matthias Choschzick, Paula Lassen, Annette Lebeau, +8

Modern Pathology

Breast OncologyMedicinePathologyCancer GenomicsCancer Biology +7

p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer

Patrick Lebok, Magdalena Roming, Martina Kluth, +19

Oncotarget

Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer

Matthias Choschzick, Annette Lebeau, Andreas H. Marx, +8

Human Pathology

Tumor BiologyBreast OncologyCell DivisionGene Amplification FrequencyMedicine +7

Cyclin D1 gene amplification is highly homogeneous in breast cancer

Eike Burandt, Martin Grünert, Annette Lebeau, +14

Breast Cancer

Tumor BiologyBreast OncologyMedicineBreast CancerCancer Biology +6

8p deletion is strongly linked to poor prognosis in breast cancer

Patrick Lebok, Anja Mittenzwei, M Kluth, +21

Cancer Biology & Therapy

Breast OncologyCancer RiskTumor HeterogeneityMedicinePathology +11